作者
Christoph Kraus, Daniel Wasserman, Ioline D Henter, Elia Acevedo-Diaz, Bashkim Kadriu, Carlos A Zarate Jr
发表日期
2019/10/1
来源
Drug discovery today
卷号
24
期号
10
页码范围
2033-2043
出版商
Elsevier Current Trends
简介
Highlights
  • The recent paradigm shift in drug development due to ketamine is described.
  • A historical overview of novel and repurposed antidepressant drugs is provided.
  • Mechanisms for ketamine and other novel agents with antidepressant effects are reviewed.
  • The antidepressant properties of hallucinogenic drugs are assessed.
Recent research demonstrating that the glutamatergic modulator ketamine has rapid, robust, and sustained antidepressant effects has been a turning point in drug discovery for depression. The recent FDA approval of esketamine for adults with treatment-resistant major depressive disorder (MDD) has further underscored the relevance of this agent in spurring investigation into novel and mechanistically distinct agents for use in depression. Over the past two decades, ketamine research has ushered in a new wave of studies seeking to not only identify its mechanism of action but also to …
引用总数
20202021202220232024151619144
学术搜索中的文章
C Kraus, D Wasserman, ID Henter, E Acevedo-Diaz… - Drug discovery today, 2019